Open-Label Influenza Vaccine Evaluation

NACompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

September 30, 2018

Conditions
Immune Response
Interventions
BIOLOGICAL

High Dose Influenza vaccine

Licensed and FDA approved Fluzone HD vaccine to be administered to study participants

BIOLOGICAL

Adjuvanted Influenza vaccine

Licensed and FDA approved FluAd vaccine to be administered to study participants

BIOLOGICAL

Standard Dose Influenza vaccine

Licensed and FDA approved Fluvirin vaccine to be administered to study participants

BIOLOGICAL

Recombinant Influenza vaccine

Licensed and FDA approved FluBlok vaccine to be administered to study participants

Trial Locations (1)

54449

Marshfield Clinic - Marshfield Center, Marshfield

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Marshfield Clinic Research Foundation

OTHER

NCT02872311 - Open-Label Influenza Vaccine Evaluation | Biotech Hunter | Biotech Hunter